Lecigon

Levodopa/Carbidopa/Entacapone, the active ingredients in Lecigon, is a combination antiparkinson agent presented as an oral tablet for intestinal use. The formulation combines a dopamine precursor, a peripheral decarboxylase inhibitor, and a COMT inhibitor to enhance central dopamine availability. It is employed to improve motor symptoms and reduce off‑periods in adults with Parkinson's disease who are receiving levodopa therapy.

GNH USA supplies Lecigon as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Lecigon, a levodopa/carbidopa/entacapone combination, is indicated for Parkinson's disease management as part of levodopa therapy.

Parkinson's disease (adjunct to levodopa): improves motor fluctuations and extends levodopa effect. Early-stage Parkinson's disease (combined therapy): enhances dopaminergic response to reduce symptom onset. Advanced Parkinson's disease with wearing‑off phenomena: decreases off‑time and improves daily functioning.

Lecigon may be associated with a range of adverse reactions, which are categorized by frequency.

Common Side Effects: - Nausea - Vomiting - Dyskinesia - Orthostatic hypotension - Insomnia - Constipation

Serious or Rare Side Effects: - Severe liver injury - Neuroleptic malignant syndrome - Anaphylactic or severe allergic reactions - Suicidal ideation or severe depression

When prescribing Lecigon, clinicians should observe several precautionary measures to ensure patient safety.

Monitor blood pressure: watch for orthostatic hypotension, especially at therapy initiation. Assess hepatic function: entacapone may affect liver enzymes; periodic liver tests are recommended. Evaluate psychiatric status: monitor for depression, hallucinations, or suicidal thoughts. Adjust dose in renal impairment: reduced clearance may require careful titration. Avoid use in patients with narrow‑angle glaucoma: dopaminergic activity can increase intra‑ocular pressure. Store at room temperature: keep in the original container, protect from moisture and light.

Lecigon can interact with other medicines, altering its efficacy or safety profile.

Major Interactions (Avoid): - MAO‑B inhibitors (e.g., selegiline, rasagiline): risk of hypertensive crisis when combined with levodopa. - Non‑selective MAO inhibitors (e.g., phenelzine): may cause severe hypertension. - High‑dose anticholinergic drugs (e.g., benztropine): can mask levodopa side effects and increase confusion.

Moderate Interactions (Monitor Closely): - Antihypertensive agents: additive blood pressure lowering may require dose adjustment. - SSRIs or other serotonergic drugs: may increase risk of serotonin syndrome. - NSAIDs: may enhance risk of gastrointestinal bleeding. - Iron or vitamin B6 supplements: can reduce levodopa absorption; separate dosing times.